Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab + Octreotide in Metastatic Neuroendocrine Tumors
NCT00781911Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2009
- Primary completion
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cixutumumab in Carcinoid Tumor (CT) and islet cell carcinoma (ICC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Feb 2009; status: completed.
02
Drugs
cixutumumab
03
Conditions
Carcinoid Tumor (CT)islet cell carcinoma (ICC)
Beyond the preview
Go deeper on NCT00781911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781911.